Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205641 | 0.86 | AAK1 (0.38) | AAK1MEN1KMT2ATSHR | |
| SCHEMBL26205635 | 0.85 | TSHR (0.42) | AAK1MEN1KMT2ALMNATSHR | |
| SCHEMBL26205648 | 0.82 | GRM2 (0.35) | AAK1LMNA | |
| SCHEMBL26205643 | 0.80 | GPR88 (0.35) | LMNATSHR | |
| SCHEMBL26205631 | 0.78 | MAPT (0.44) | MEN1KMT2ALMNATSHR | |
| SCHEMBL22525454 | 0.78 | AAK1 (0.61) | AAK1 | |
| SCHEMBL26205646 | 0.78 | PTGER1 (0.33) | MEN1KMT2A | |
| SCHEMBL26205653 | 0.77 | PKM (0.33) | — | |
| SCHEMBL26205632 | 0.77 | SMN1; SMN2 (0.36) | MEN1KMT2ALMNA | |
| SCHEMBL26205633 | 0.76 | HSD17B10 (0.48) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | AAK1 2860/4885DGAT1 3352/4885MEN1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.